NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Dretzke J, Edlin R, Round J, et al. A Systematic Review and Economic Evaluation of the Use of Tumour Necrosis Factor-Alpha (TNF-α) Inhibitors, Adalimumab and Infliximab, for Crohn's Disease. Southampton (UK): NIHR Evaluation, Trials and Studies Coordinating Centre (UK); 2011 Feb. (Health Technology Assessment, No. 15.6.)

Cover of A Systematic Review and Economic Evaluation of the Use of Tumour Necrosis Factor-Alpha (TNF-α) Inhibitors, Adalimumab and Infliximab, for Crohn's Disease

A Systematic Review and Economic Evaluation of the Use of Tumour Necrosis Factor-Alpha (TNF-α) Inhibitors, Adalimumab and Infliximab, for Crohn's Disease.

Show details

Appendix 5Extraction of data from published graphs

Scans of published graphs were overlayed with a grid, printed, enlarged to A3 and then used to extract data. The data were used to redraw the graph and compare with the original. Examples are shown below.

Scan of published graph with grid overlay

(CiC information has been removed.)

Scan of published graph with grid overlay

(CiC information has been removed.)

Scans of published graphs overlayed with graphs redrawn using data extracted from grid-overlayed originals

(CiC information has been removed.)

© 2011, Crown Copyright.

Included under terms of UK Non-commercial Government License.

Bookshelf ID: NBK100750
PubReader format: click here to try

Views

  • PubReader
  • Print View
  • Cite this Page
  • PDF version of this title (3.3M)

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...